vs

Side-by-side financial comparison of Marriott International (MAR) and TENET HEALTHCARE CORP (THC). Click either name above to swap in a different company.

Marriott International is the larger business by last-quarter revenue ($6.7B vs $5.5B, roughly 1.2× TENET HEALTHCARE CORP). TENET HEALTHCARE CORP runs the higher net margin — 11.7% vs 6.7%, a 5.0% gap on every dollar of revenue. On growth, TENET HEALTHCARE CORP posted the faster year-over-year revenue change (9.0% vs 4.1%). Over the past eight quarters, Marriott International's revenue compounded faster (5.8% CAGR vs 1.5%).

Marriott International, Inc. is an American multinational company that operates, franchises, and licenses lodging brands that include hotel, residential, and timeshare properties. Marriott International owns over 37 hotel and timeshare brands with 9,000 locations and 1,597,380 rooms across its network. Marriott International is headquartered in Bethesda, Maryland. The company is the successor to the hospitality division of the Marriott Corporation, founded by J.

Tenet Healthcare Corporation is an American for-profit multinational healthcare services company based in Dallas. Through its brands, subsidiaries, joint ventures, and partnerships including United Surgical Partners International (USPI), the company operates 65 hospitals and over 450 healthcare facilities. Tenet also runs Conifer Health Solutions, which provides healthcare support services to health systems and other clients.

MAR vs THC — Head-to-Head

Bigger by revenue
MAR
MAR
1.2× larger
MAR
$6.7B
$5.5B
THC
Growing faster (revenue YoY)
THC
THC
+4.9% gap
THC
9.0%
4.1%
MAR
Higher net margin
THC
THC
5.0% more per $
THC
11.7%
6.7%
MAR
Faster 2-yr revenue CAGR
MAR
MAR
Annualised
MAR
5.8%
1.5%
THC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MAR
MAR
THC
THC
Revenue
$6.7B
$5.5B
Net Profit
$445.0M
$644.0M
Gross Margin
Operating Margin
11.6%
15.4%
Net Margin
6.7%
11.7%
Revenue YoY
4.1%
9.0%
Net Profit YoY
-2.2%
12.6%
EPS (diluted)
$1.67
$4.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MAR
MAR
THC
THC
Q4 25
$6.7B
$5.5B
Q3 25
$6.5B
$5.3B
Q2 25
$6.7B
$5.3B
Q1 25
$6.3B
$5.2B
Q4 24
$6.4B
$5.1B
Q3 24
$6.3B
$5.1B
Q2 24
$6.4B
$5.1B
Q1 24
$6.0B
$5.4B
Net Profit
MAR
MAR
THC
THC
Q4 25
$445.0M
$644.0M
Q3 25
$728.0M
$579.0M
Q2 25
$763.0M
$522.0M
Q1 25
$665.0M
$622.0M
Q4 24
$455.0M
$572.0M
Q3 24
$584.0M
$681.0M
Q2 24
$772.0M
$477.0M
Q1 24
$564.0M
$2.3B
Operating Margin
MAR
MAR
THC
THC
Q4 25
11.6%
15.4%
Q3 25
18.2%
16.8%
Q2 25
18.3%
15.6%
Q1 25
15.1%
18.1%
Q4 24
11.7%
16.2%
Q3 24
15.1%
21.3%
Q2 24
18.6%
14.9%
Q1 24
14.7%
61.2%
Net Margin
MAR
MAR
THC
THC
Q4 25
6.7%
11.7%
Q3 25
11.2%
10.9%
Q2 25
11.3%
9.9%
Q1 25
10.6%
11.9%
Q4 24
7.1%
11.3%
Q3 24
9.3%
13.3%
Q2 24
12.0%
9.3%
Q1 24
9.4%
43.5%
EPS (diluted)
MAR
MAR
THC
THC
Q4 25
$1.67
$4.22
Q3 25
$2.67
$3.86
Q2 25
$2.78
$3.14
Q1 25
$2.39
$4.27
Q4 24
$1.64
$3.79
Q3 24
$2.07
$4.89
Q2 24
$2.69
$2.64
Q1 24
$1.93
$21.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MAR
MAR
THC
THC
Cash + ST InvestmentsLiquidity on hand
$358.0M
$2.9B
Total DebtLower is stronger
$15.0B
$13.1B
Stockholders' EquityBook value
$-3.8B
$4.2B
Total Assets
$27.5B
$29.7B
Debt / EquityLower = less leverage
3.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MAR
MAR
THC
THC
Q4 25
$358.0M
$2.9B
Q3 25
$678.0M
$3.0B
Q2 25
$671.0M
$2.6B
Q1 25
$523.0M
$3.0B
Q4 24
$396.0M
$3.0B
Q3 24
$394.0M
$4.1B
Q2 24
$349.0M
$2.9B
Q1 24
$429.0M
$2.5B
Total Debt
MAR
MAR
THC
THC
Q4 25
$15.0B
$13.1B
Q3 25
$14.4B
$13.1B
Q2 25
$14.5B
$13.1B
Q1 25
$14.1B
$13.1B
Q4 24
$13.1B
$13.1B
Q3 24
$12.7B
$12.8B
Q2 24
$12.2B
$12.8B
Q1 24
$11.7B
$12.8B
Stockholders' Equity
MAR
MAR
THC
THC
Q4 25
$-3.8B
$4.2B
Q3 25
$-3.1B
$4.0B
Q2 25
$-3.0B
$3.7B
Q1 25
$-3.2B
$4.2B
Q4 24
$-3.0B
$4.2B
Q3 24
$-2.4B
$3.8B
Q2 24
$-2.1B
$3.5B
Q1 24
$-1.6B
$3.5B
Total Assets
MAR
MAR
THC
THC
Q4 25
$27.5B
$29.7B
Q3 25
$27.8B
$29.4B
Q2 25
$27.3B
$28.7B
Q1 25
$26.7B
$29.2B
Q4 24
$26.2B
$28.9B
Q3 24
$26.2B
$29.4B
Q2 24
$25.7B
$29.3B
Q1 24
$25.8B
$28.9B
Debt / Equity
MAR
MAR
THC
THC
Q4 25
3.10×
Q3 25
3.26×
Q2 25
3.49×
Q1 25
3.13×
Q4 24
3.14×
Q3 24
3.33×
Q2 24
3.67×
Q1 24
3.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MAR
MAR
THC
THC
Operating Cash FlowLast quarter
$829.0M
$731.0M
Free Cash FlowOCF − Capex
$367.0M
FCF MarginFCF / Revenue
6.6%
Capex IntensityCapex / Revenue
6.6%
Cash ConversionOCF / Net Profit
1.86×
1.14×
TTM Free Cash FlowTrailing 4 quarters
$2.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MAR
MAR
THC
THC
Q4 25
$829.0M
$731.0M
Q3 25
$1.1B
$1.1B
Q2 25
$643.0M
$936.0M
Q1 25
$647.0M
$815.0M
Q4 24
$318.0M
$-331.0M
Q3 24
$880.0M
$1.0B
Q2 24
$772.0M
$747.0M
Q1 24
$779.0M
$586.0M
Free Cash Flow
MAR
MAR
THC
THC
Q4 25
$367.0M
Q3 25
$951.0M
$778.0M
Q2 25
$488.0M
$743.0M
Q1 25
$512.0M
$642.0M
Q4 24
$-24.0M
$-661.0M
Q3 24
$706.0M
$829.0M
Q2 24
$647.0M
$602.0M
Q1 24
$670.0M
$346.0M
FCF Margin
MAR
MAR
THC
THC
Q4 25
6.6%
Q3 25
14.7%
14.7%
Q2 25
7.2%
14.1%
Q1 25
8.2%
12.3%
Q4 24
-0.4%
-13.0%
Q3 24
11.3%
16.2%
Q2 24
10.0%
11.8%
Q1 24
11.2%
6.4%
Capex Intensity
MAR
MAR
THC
THC
Q4 25
6.6%
Q3 25
2.2%
5.3%
Q2 25
2.3%
3.7%
Q1 25
2.2%
3.3%
Q4 24
5.3%
6.5%
Q3 24
2.8%
4.2%
Q2 24
1.9%
2.8%
Q1 24
1.8%
4.5%
Cash Conversion
MAR
MAR
THC
THC
Q4 25
1.86×
1.14×
Q3 25
1.50×
1.83×
Q2 25
0.84×
1.79×
Q1 25
0.97×
1.31×
Q4 24
0.70×
-0.58×
Q3 24
1.51×
1.53×
Q2 24
1.00×
1.57×
Q1 24
1.38×
0.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MAR
MAR

Segment breakdown not available.

THC
THC

Other$2.9B52%
Health Care Patient Service$1.4B25%
Equity Method Investment Nonconsolidated Investee Or Group Of Investees$1.2B22%
Health Care Other Sources$56.0M1%

Related Comparisons